Spondyloarthritis: Clinical suspicion, diagnosis, and sports

Current Sports Medicine Reports

Volumn 8, Issue 1, 2009, Pages 29-34

  Harper, Brock E ^a   Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; INDOMETACIN; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; BACKACHE; CERVICAL SPINE FRACTURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; EXERCISE; HUMAN; INFLAMMATION; JOINT FUNCTION; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; SPINE MOBILITY; SPORT INJURY; TREATMENT FAILURE;

ATHLETIC INJURIES; HUMANS; SPONDYLARTHRITIS; SPORTS; SPORTS MEDICINE;

EID: 67651230678     PISSN: 1537890X     EISSN: 15378918     Source Type: Journal    
DOI: 10.1249/JSR.0b013e3181967ac6     Document Type: Review

References (31)

1. Boden BP, Jarvis CG. Spinal injury in sports. Neurol. Clinic. 2006;26: 63-78.
2. Brandt HC, Spiller I, Song JH, Vahldiek JL, Rudwaleit M, Sieper J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarhritis. Ann. Rheum. Dis. 2007;66:1479-84.
3. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis & Rheumatism. 2008;59:1270-8.
4. Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC, et al. MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. Am. J. Roentgenol. 2006;187:1420-6.
5. Chen J, Liu C, and Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Sys. Rev. 2006;4:CD004524.
6. Clegg DO, Reda DJ, Abdellatif M. Comparison of Sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies. Arthritis & Rheumatism. 1999;42(11):2325-9.
7. Davis JC Jr, van der Heijde DM, Braun JC, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2008;67:346-52.
8. Elgan M, Khan M. Does physical therapy still have a place in the treatment of ankylosing spondylitis? Curr. Opin. Rheum. 2008;20:282-6.
9. Feldtkaller E, Vosse D, Geusens P, van der Linden S. Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheum. Int. 2006;26:234-9.
10. Fernandez-de-las-Peñas F, Alonso-Blanco C, Alguacil-Diego I, Miangolarra-Page J. One year follow-up of two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am. J. Phys. Med. Rehabil. 2006;85:559-67.
11. Gladman DD, Inman RD, Cook RJ, et al. International Spondyloarthritis Interobserver Reliability Exercise - The INSPIRE Study: I. Assessment of Spinal Measures. J. Rheumatol. 2007;34:1733-9.
12. Healy P, Helliwell P. Classification of the SpA. Curr. Op. Rheum. 2005;17:395-9.
13. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part 1. Arthritis & Rheumatism. 2008;58:15-25.
14. Heuft-Dorenbosch L, Landewé R, Weijers R, et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann. Rheum. Dis. 2006;65:804-8.
15. Ince G, Sarpel T, Purgun B, Erdogen S. Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys. Ther. 2006;86:924-35.
16. Kane D, Pathare S. Early psoriatic arthritis. Rheum. Dis. Clin. N. Am. 2005;31:641-57.
17. Khan, M. Update on spondyloarthropathies. Ann. Intern. Med. 2002;136:896-907.
18. Lim H, Moon Y, Lee M. Effects of home-based daily exercise therapy on joint mobility, daily activity, pain and depression in patients with ankylosing spondylitis. Rheum. Int. 2005;25:225-9.
19. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J. Rheumatol. 2002;29:511-5.
20. Puhakka K, Jurik AG, Schiottz-Christense B, et al. Magnetic resonance imaging of sacroiliitis in early seronegative spondyloarthropathy: abnormality correlated to clinical and laboratory findings. Rheumatology. 2004;43:234-7.
21. Reveille J, Arnett F. Spondyloarthritis: update in pathogenesis & management. Am. J. Med. 2005;118:592-603.
22. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis. Arthritis & Rheumatism. 2006;54:569-78.
23. Rudwaleit M, Khan M, Sieper J. The challenge of diagnosis and classification of ankylosing spondylitis. Arthritis & Rheumatism. 2005;52:1000-8.
24. Rudwaleit M, Van der Heijde D, Khan M, et al. How to diagnose axial spondyloarthropathy early. Ann. Rheum. Dis. 2004;63:535-43.
25. th ed. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Philadelphia: Mosby-Elsevier, 2008, pp. 1131-41.
26. Sieper J, Braun J, Rudwaleit M, van der Heijde D. Ankylosing spondylitis: an overview. Ann. Rheum. Dis. 2002;61 (Suppl. III) :III8-18.
27. Sieper J, Rudwaleit W, Braun J, et al. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis & Rheumatism. 2002;46:319-27.
28. Thumbikant P, Hariharan RP, Ravichandran G, McCllelland MR, Mathew KM. Spinal cord injury in patients with ankylosing spondylitis. Spine. 2007;32:2989-95.
29. Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol. Int. 2006;26:663-8.
30. Uhrin Z, Kuzis S, Ward M. Exercise & changes in health status in patients with ankylosing spondylitis. Arch. Int. Med. 2000;160:2969-75.
31. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. Epub ahead of print, 2008.